1. Introduction {#sec1}
===============

The COVID-19 pandemic has tightened its grip on India. India does not figure in the most severely affected countries \[[@bib1]\] but fares worse than the top affected nations in key medical infrastructure and health care investments. India has fewer hospital beds and doctors per 1000 people than any of the countries affected by COVID-19 \[[@bib2]\]. In terms of personal hygiene, a section of the population may not even have adequate facilities for washing hands with soap frequently or hand sanitizers, a basic preventive measure \[[@bib3]\]. Moreover, those who progress into critical stages would require intensive care and this can pose a major challenge for the limited hospital resources and capacities in case of a sudden spike in infections.

Considering the fact that COVID-19 requires a structured approach covering preventive care, management in early stages of confirmed disease as well as hospital care for moderately and critically ill patients, it is imperative that the capacity of the AYUSH sector is harnessed to ensure optimal use of the scarce health care resources available in the country. The World Health Organization has also recommended inclusion of traditional medicine in its COVID-19 strategic preparedness and response plan \[[@bib4]\]. The focus should not be to just deploy this workforce as a standby option, but to utilize its therapeutic management potential in complementing the treatment administered by modern medicine. Pluralism is one of the core principles in Indian health system as outlined in the National Health Policy 2017, which calls for integrative health practices to achieve national health goals and objectives \[[@bib5]\].

To move in this direction, it becomes necessary to develop an Ayurvedic diagnostic and treatment protocol for integration into the standard treatment guidelines of COVID-19. We have a precedent in China, where Traditional Chinese Medicine (TCM) doctors were actively involved in the treatment of COVID-19 patients and the TCM diagnostic classification as well as treatment was integrated into the official management guideline. More than 60,000 patients received TCM medications based on this protocol \[[@bib6]\] and TCM interventions have also been included in the official handbooks that recommend protocols for management of COVID-19 \[[@bib7]\]. TCM interventions have also figured in research studies that have been initiated to discover a remedy for the disease \[[@bib8]\].

In this paper, we are demonstrating that it is possible for Allopathic and Ayurvedic doctors to cooperate and work together to understand the disease better from an Ayurvedic perspective. This will be the first step to develop an integrative treatment protocol incorporating Ayurveda for best outcomes in the management of COVID-19.

An Ayurvedic assessment of the disease can help to classify the clinical presentations of COVID-19 on the basis of the *tridoṣa* framework (the three *doṣas* called *vāta*, *pitta* and *kapha* represent the self-regulatory mechanisms of the body, the failure of which leads to development of disease). It is seen that the clinical presentations of the patients are different with the lower respiratory, gastrointestinal or upper respiratory systems being variably affected in patients \[[@bib9]\]. The question that we are addressing in this paper is whether such clustering of symptoms can be interpreted based on an Ayurvedic understanding of the pathogenesis with reference to imbalance of *tridoṣas*. This would lead to development of appropriately specific Ayurvedic interventions that can be integrated into the evolving COVID management protocol.

2. Methodology {#sec2}
==============

In the prevailing circumstances, Ayurvedic physicians are unable to directly examine COVID-19 patients clinically. For this reason, a triangulation approach has been used for the study. The steps were 1) Study the existing clinical data from review of current scientific literature, 2) Review prospective clinical data collected from hospital documentation and regular discussion with the clinicians treating COVID19 patients and 3) Review relevant Ayurveda literature with the inputs of expert clinicians. The three-pronged strategy in the respective sequence covered the following aspects:

A detailed literature review of the reported typical clinical presentation based on existing data sources such as journal articles and interim clinical guidance on management of patients by agencies such as US CDC (as on April 30, 2020) was undertaken \[[@bib9]\]. The global overview reports were screened for key terms relating to COVID19 symptoms, pathogenesis and stagewise understanding. As the clinical presentation is found to vary widely, research papers reporting clinical symptoms of patient cohorts from different parts of the world were also reviewed to identify outliers and atypical presentations.

A quick scoping of PubMed found around 569 articles on COVID19 based on a search with the key words COVID 19, symptoms. It was found that papers reported symptoms related to COVID-19 from specific clusters and cohorts of patients and the information could not be generalized to the larger population. Interim guidelines issued by international agencies like US CDC and WHO \[[@bib10]\], which were drafted by reviewing published research papers were selected to study the clinical presentation of COVID-19. Eighteen most relevant papers reviewed by US CDC and WHO were shortlisted for a detailed review based on the following inclusion criteria -- 1) Paper reports from large samples of patients from representative regions of the outbreak of COVID-19, 2) Papers reporting typical presentations of the disease, 3) Papers reporting atypical presentations of the disease.

Clinical case documentations of fourteen COVID-19 patients treated at Medanta Hospital, Gurgaon was examined prospectively. Necessary ethical approval for patient data review was obtained and a confidentiality agreement was signed with the hospital. Baseline data was compiled with a structured questionnaire covering clinical symptomatology and laboratory reports of each patient at the time of admission. This data also included assessment of co-morbidities and other prescriptions at the time of admission. A second set of data was collated, summarizing assessments done during hospital stay. Regular discussions and interactions with the treating allopathic clinicians during the course of management provided individual case narratives and focused clinical perspectives about each patient.

Subsequently, an independent analysis of Ayurvedic literature was carried out. This included three major classical texts (*Bṛhattrayī -- Carakasamhitā, Suśrutasaṃhitā, Aṣṭāṅgahṛdayaṃ* and their important commentaries (by *Cakrapāṇi*, *Aruṇadatta*, *Hemādri*, *Indu* and *Dalhaṇa).* In addition, specific diagnostic literature viz. the *Jvaranirṇaya* (an exclusive text on management of fevers), *Yogaratnākara* (a medieval textbook on Ayurveda), *Bhāvaprakasa* and *Mādhavanidāna* (a classical text on diagnosis, etiopathogenesis and differential stage wise classifications) were also studied. Five clinical conditions described in these texts were examined to develop correlation with COVID-19. These were fever (*jvara*), cough (*kāsa*), dyspnoea (*śvāsa*), consumption (*rājayakṣmā*) and poisoning (*viṣa*) including Ayurvedic descriptions of the co-morbidities that indicate poor prognostic outlook for COVID-19. Since COVID-19 is a new disease and not previously described in Ayurvedic classical texts, a detailed study of the etiology (*nidāna*), status of *tridoṣa*, structural elements (*dūṣya*) and site of disease (*sthāna*) was done. The book *Siddhāntanidāna* by Gaṇanatha Sen was reviewed to understand approaches to study new diseases based on principles of Ayurveda. The analysis of sections on epidemics (*janapadodhvaṃsa*) and diseases of exogenous origin (*āgantukavikāra*) was also undertaken. Host-pathogen specific interactions as observed in COVID-19 were analysed on the basis of the Ayurvedic understanding of the clinical progression of *āgantuka* diseases. The pathogenesis of the disease was traced from the point of contact with the causative agent (SARS-CoV-2) and its development through the asymptomatic, presymptomatic, mild, moderate, severe and critical stages culminating in recovery or death. This was also corroborated with insights from experienced Ayurveda physicians in the team.

3. Findings & results {#sec3}
=====================

3.1. Disease profile as per current scientific literature {#sec3.1}
---------------------------------------------------------

The incubation period of the SARS-CoV-2 virus is approximately two weeks. Symptoms can manifest within 4--5 days after infection and majority will become sick by 11--12 days. In rare cases it can be delayed even up to 24 days \[[@bib11]\].

According to the US CDC, symptoms present at onset of COVID-19 are highly variable. However, in the stage of full-blown disease, 83--99 percent of patients develop fever, 59--82 percent have cough, 44--77 percent have fatigue, 40--84 percent have anorexia, 31--40 patients have shortness of breath, 28--33 percent have sputum production and 11--35 percent have myalgias \[[@bib9]\].

Fever, Cough (dry) and Shortness of breath are considered to be the cardinal symptoms of COVID-19. Recently, CDC has added other symptoms to the list like Chills, Repeated shaking with chills, Muscle pain, Headache, Sore throat and New loss of taste or smell \[[@bib12]\].

Atypical presentations are mainly seen in older adults and persons with co-morbidities \[[@bib13]\]. Fever was absent in up to 44 percent of patients at the onset of the disease, but 89 percent developed fever during hospital stay \[[@bib14]\].

Some patients present with gastrointestinal symptoms like diarrhea and nausea and no respiratory symptoms \[[@bib15]\]. Vomiting and diarrhea are seen only in less than 10% of the cases. Likewise, upper respiratory symptoms like sore throat, rhinorrhea and headache are sporadically reported. Hemoptysis may also be seen in a similar percentage of cases \[[@bib14],[@bib16], [@bib17], [@bib18]\]. Skin eruptions have been rarely reported \[[@bib19]\]. It has been observed in certain cohorts that patients who exhibit gastrointestinal symptoms tend to have longer time from onset to admission and more laboratory derangements \[[@bib20]\]. Although age is a higher risk for a bad prognosis, even people in the younger age group without co-morbidities have higher risk of death than that of seasonal influenza \[[@bib21]\]. Patients with comorbidities like diabetes, hypertension, cardiovascular disease, cancer are at a high risk for complications and death due to COVID-19 \[[@bib22]\].

Interestingly, patients tested positive for COVID-19 have also been reported to be asymptomatic as noticed with patients aboard the ship Diamond Princess \[[@bib23]\]. Though subsequent studies have been conducted, the percentage of this occurrence is not accurately known. One study estimated that more than one fourth tested positive for COVID-19 could be asymptomatic \[[@bib24]\]. Another study said up to four fifths of those tested positive could be asymptomatic \[[@bib25]\]. It has been reported that asymptomatic patients can have typical ground-glass opacities or patchy shadowing in the CT Scans \[[@bib26],[@bib27]\]. See [Table 1](#tbl1){ref-type="table"} for typical and atypical symptoms of COVID-19.Table 1Presentation of clinical symptoms in COVID-19.Table 1TYPICAL SYMPTOMSEARLYLATECOMPLICATIONS**MAJOR**Fever (83--99%), Cough (59--82%)Breathing Difficulty (31--40%), Mild PneumoniaHypoxia, Pneumonia, ARDS, Coagulopathy**COMMON**ChillsRepeated shaking with chillsMyalgiaHeadacheSore throatNew loss of taste or smell**ASSOCIATED**Anorexia (40--84%)Fatigue (44--70%)Sputum (28--33%)**ATYPICAL SYMPTOMSSPORADIC**\< **10%**ConfusionHaemoptysisVomitingNauseaDiarrhoea**Being InvestigatedRARE**Skin eruptions

The US CDC classifies COVID-19 into the following categories based on severity of the presentation.•Mild to moderate (mild symptoms up to mild pneumonia): 81%•Severe (dyspnea, hypoxia, or \>50% lung involvement on imaging): 14%•Critical (respiratory failure, shock, or multiorgan system dysfunction): 5%

In the critical stage of COVID-19, patients present with severe hypoxemia, pneumonia and ARDS. If the disease becomes severe, then shortness of breath indicating pneumonia can develop with or without high grade fever. It can progress to severe pneumonia and ARDS of varying severity, which can be life threatening. In the event of an over-exuberant immune response, complications can arise as a result of damage to the lungs. Pneumonia may be mild or severe, ARDS may be mild, moderate or severe requiring oxygenation or ventilator support. Especially in some young people, the immune system can go into an overdrive and manifest the cytokine storm syndrome, which can cause severe lung damage and death. The SARS-CoV-2 induced infection can also be associated with a coagulopathy. CAC (COVID-19 associated coagulopathy) is the acronym used to describe the coagulation changes in COVID-19 patients \[[@bib28]\].

In an observational study from Wuhan, China, cardiac injury was seen in 19.7% of patients with confirmed coronavirus disease 2019 (COVID-19) and was an independent predictor of in-hospital mortality \[[@bib29]\]. Acute Hemorrhagic Necrotizing Encephalopathy (AHNE), a rare complication of influenza and other viral infections has also been reported in COVID-19 \[[@bib30]\]. Liver injury has also been reported in some patients \[[@bib31]\]. Sepsis or Septic shock can also set in leading to life threatening situation \[[@bib10]\].

Literature review of published studies reveal that COVID-19 patients can have varied clinical presentation with absence of symptoms or atypical presentations in a number of patients.

3.2. Clinical data from a cohort of COVID-19 patients {#sec3.2}
-----------------------------------------------------

### 3.2.1. Patient background {#sec3.2.1}

We examined case records of 14 COVID-19 patients treated at Medanta Hospital, Gurgaon. All were Italian citizens who came to India as tourists and were tested for COVID-19 when some of them developed symptoms and were admitted to Medanta Hospital.

### 3.2.2. Patient age group {#sec3.2.2}

Except for one patient aged 45, all other patients were in the age group ranging from 60 to 80 years.

### 3.2.3. Co-morbidities {#sec3.2.3}

Seven of the patients had comorbidities out of which ten had diseases that have been identified as high risk for patients with a diagnosis of COVID-19. There were six patients with hypertension, three with cardiac diseases, one with diabetes and one with benign prostate hypertrophy.

### 3.2.4. Condition at admission {#sec3.2.4}

Five patients were asymptomatic at the time of admission and the other nine patients had only mild symptoms.

### 3.2.5. Symptom profile {#sec3.2.5}

In the course of hospital stay, all fourteen patients developed cough, which was the most prominent symptom seen in this cohort. The next common symptom reported was throat pain, which was seen in twelve patients. The third common symptom was fever, which was mostly intermittent and was seen in eleven of the patients. Headache and myalgia were seen in nine and eight patients respectively. Only four patients developed dyspnea, of which two had mixed (inspiratory and expiratory type). Other symptoms reported in decreasing order of frequency are were insomnia, giddiness, loss of appetite, fatigue, severe anxiety, nasal obstruction, nasal discharge, nausea, diarrhea, arthralgia, cold chills, general edema, delerium and confusion. In all, twenty symptoms were reported in this cohort of COVID-19 patients. See [Table 2](#tbl2){ref-type="table"} for symptom profile of the patients.Table 2Symptom profile of cohort of 14 COVID-19 patients.Table 21234567891011121314**Cough (100%)**√√√√√√√√√√√√√√**Throat Pain (86.71%)**√√√√√√√√√√√√**Fever (78.57%)**√√√√√√√√√√√**Headache (64.29%)**√√√√√√√√√**Myalgia (57.14%)**√√√√√√√√**Dyspnoea (28.58%)**√√√√**Insomnia (28.58%)**√√√√**Giddiness (21.43%)**√√√**Loss of Appetite (14.29%)**√√**Fatigue (14.29%)**√√**Severe Anxiety (14.29%)**√√**Nasal Obstruction (14.29%)**√√**Nasal discharge (7.14%)**√**Nausea (7.14%)**√**Diarrhoea (7.14%)**√**Arthralgia (7.14%)**√**Cold Chills (7.14%)**√**General Edema (7.14%)**√**Delerium (7.14%)**√**Confusion (7.14%)**√**CO-MORBIDITIESHypertension (42.86%)**√√√√√√**Cardiac Disease (21.43%)**√√√**Diabetes (7.14%)**√**BPH (7.14%)**√**HABITSSmoking (21.43%)**√√√**Clinical Course**SevereCriticalSevereSevere**Outcome**RRRRRDRRRRRRRR

### 3.2.6. Clinical course {#sec3.2.6}

All the patients who developed dyspnea progressed to Acute Respiratory Distress and required oxygen support. Three of them were hypertensive, one also had cardiovascular disease and one had BPH. Patient 6, who was hypertensive and had cardiac disease, became very critical requiring ventilatory support as well as prolonged stay in hospital and eventually died on the 37th day. This patient (P6) tested negative on the 18th day but again tested positive on 24th day before turning severely critical. P6 had exhibited severe anxiety and irritability during the hospital stay and also reported the maximum number of thirteen symptoms. Patient 7 was the fastest to recover, testing negative on the fifteenth day and was discharged on the eighteenth day. All other patients tested negative on the seventeenth day and were discharged on the twentieth day.

### 3.2.7. Medications {#sec3.2.7}

Concomitant medications for co-morbidities were continued. Symptoms like fever and aches were managed with antipyretics and analgesics. Antacids were administered for gastrointestinal symptoms. Few patients were also administered sedatives. Vitamin supplements, especially Vitamin C was also administered. Ritonavir-lopinavir combination was administered to three of the four patients who developed ARDS. Hydroxychloroquine and Azithromycin were administered to two of the patients who became severe including the one patient who died.

### 3.2.8. Comparison of patient data with findings from literature review {#sec3.2.8}

We found that the clinical presentation and course of the cohort of COVID-19 patients matched more or less with findings from literarure review of published papers. In this cohort, 35% of patients were asymptomatic at the time of admission and except for three patients who developed severe disease (21.43%) and one patient who became critical (7.14%), others developed mild to moderate symptoms during hospital stay (71.43%). P6 became critical and died (7.14%). The higher percentage of patients in the severe and critical category is an expected finding, considering the advanced age of the patients as well as presence of co-morbidities. Cough, throat pain and fever were dominant in this cohort, which have been reported as typical symptoms of COVID-19 patients. The symptoms seen were mainly related to upper and lower respiratory tract. Some patients also reported symptoms related to gastrointestinal tract. Apart from other generalized symptoms like fever and myalgia, psychological symptoms were also seen in some patients. A critical analysis of the data from this cohort of patients from an Ayurvedic perspective is included in the section on discussion. See [Table 3](#tbl3){ref-type="table"} for summary of clinical data from this cohort of patients.Table 3Analysis of clinical symptoms of a cluster of COVID-19 patients.Table 3Patient No.AgeSexCo-MorbidityBaselineClinical CourseProgressActive MedicationsConcomitant Medications continuedLength of StayTest negativeOutcome\
R-Recovered D - Death**P1**64FHypertensionMildCough, throat pain, feverARDS, Oxygen support requiredAlprazolam, Alfuzosin, Diclofenac Gel, Hydrochlorothiazide, Olmesartan, Nebivolol, Tramadol + Paracetamol, Vitamin CAntihyptertensive medicines2017R**P2**66MHypertension, DiabetesAsymptomaticCough, throat pain, myalgia, headacheAmlodipine, Atorvastatin,\
Liquid Paraffin, Metformin Hcl., Magnesium Hydroxide and Sodium picosulphate, Multivitamins,\
Vitamin CAntidiabetic medicines2017R**P3**45FHypertension, Cardiac diseaseMildIntermittent fever, cough, myalgiaAcetylsalicylic acid, Alprazolam, Diclofenac Gel, Hydrogen Peroxide, Pantoprazole, Sodium chloride Drops, Telmisartan and hydrochlorothiazide,\
Vitamin CAntihyptertensive medicines2717R**P4**68FAsymptomaticIntermittent fever, cough, dyspnoea, giddiness, headache, nasal obstruction, nasal discharge, throat pain, insomniaAzithromycin, Amlodipine,\
Hydrochlorothiazide, Levocetirizine, Prednisolone, Paracetamol, Potassium Chloride Inj, Propranolol,\
Vitamin CAntihypertensives Amlodipine Atorvastatin Propranolol2017R**P5**70MAsymptomaticIntermittent fever, cough, throat pain,Alprazolam, Atorvastatin, Vitamin C2017R**P6**74MHypertension, Cardiac diseaseMildIntermittent fever, cough, dyspnoea (mixed type), nasal obstruction, throat pain, oedema, insomnia, severe anxiety, delirium, confusion, giddiness, headache, cold chillsARDS, Hypoxia, Critical, VentilatorAcetazolamide, Acetylcysteine,\
Adrenaline, Albumin 20, Alprazolam, Amiodarone, Anidulafungin, Atracurium,\
Atropine, Augmentin, Pheniramine maleate, Aztreonam, Calcium gluconate,\
Ceftazidime + avibactam, Clotrimazole, Dexamethasone, Dexmedetomidine, Salbutamol sulphate and ipratropium bromide, Probiotic, Enoxaparin,\
Ensure plus, *Bacillus clausii*, Ephedrine, Furosemide, Glutaverge, Heparin, Hydrochlorothiazide, Hydrocortisone, Hydroxychloroquine, Insugen,\
Ivabradine, Lactulose, Levofloxacin, Lignocaine 2% jelly, Loperamide, Magnesium sulphate 50%, Mephentermine, Meropenem, Metronidazole, Midazolam, Mistabron, Modafinil, Montelukast, Nitroglycerin, Noradrenaline, Omega 3 fatty acids, Pantoprazole, Paracetamol inj., Piperacillin and tazobactam,\
Polymyxin b, Potassium chloride, Profol, Providac, Refresh tears, Ritonavir-lopinavir, Smofkabiven, Sodium mercapb ethan, Spironolactone, Teicoplanin, Tocilizumab, Trace elements, Tranexamic acid, Tropicamide + phenyl pyridine drops, Vitamin C Vitamin D33718, but positive again on 24th dayD**P7**70FMildCough, throat pain, myalgia, headache, feverAtorvastatin, Diclofenac gel, Etoricoxib, Paracetamol, Vitamin CAntihyptertensive medicines1815R**P8**65FMildFever, cough, throat pain, myalgia, headacheAnesthetic antacid, *Bacillus clausii*\
Esomeprazole, Liquid paraffin + MgOH2, Lansoprazole, Pantoprazole, Sodium chloride nasal spray, Vitamin CAntihyptertensive medicines2017R**P9**71FHypertension (H/o smoking), Caridac diseaseMildCough, throat pain, feverAmlodipine, Apixaban, *Bacillus clausii*, Diclofenac gel, Flecainide, Olmesartan, Paracetamol, Vitamin CAntihyptertensive medicines2017R**P10**64M(H/o smoking)MildCough, throat pain, myalgia, headacheAlprazolam, Sodium Chloride (Flexi Drip), Vitamin C2017R**P11**73FMildFever, cough, throat pain, myalgia, headachePolyethylene glycol drop, Paracetamol, Pantoprazole, Vitamin C2017R**P12**77FMildCough, myalgiaOndansetron, Rabeprazole, Vitamin C2017R**P13**68MBPHAsymptomaticIntermittent fever, cough, dyspnoea (mixed type), nausea, diarrhoea, loss of appetite, fatigue, insomnia, severe anxiety, headache, myalgia, arthralgia, giddinessARDS, Hypoxia, Oxygen Support neededAcebrophylline, Amoxycillin + Clavulanate Inj., Anesthetic Antacid, Azithromycin, *Bacillus clausii*, Chlorpheniramine Maleate, Chloroquine, Clonazepam, DNS - Aqua Plus Inj., Hydroxychloroquine, Hydrocortisone Inj., Liquid paraffin + MgOH2, Montelukast sodium, NaCl Drops, Ondansetron Inj, Oseltamivir. Pheniramine, Prednisolone,\
Rabeprazole, Ritonavir + Lopinavir, Sodium Chloride (Flexi Drip), Tocilizumab Inj., Tamsulosin, Vitamin C2017R**P14**73MHypertension (H/o smoking)AsymptomaticFever, cough, throat pain, dyspnoea, loss of appetite, fatigue, insomnia, headache,ARDSAnaesthetic antacid Syp. Alprazolam, Ondansetron, Paracetamol, Pantroprazole, Rabeprazole, Ritonavir + Lopinavir,Antihyptertensive medicines, ARB Statin, Alprazolam, Trimebutine Maleate2724R

As Ayurveda physicians do not have direct access to COVID-19 patients, it was not possible to conduct Ayurvedic clinical examination procedures like *trividhaparīkṣā*, *aṣṭasthānaparīkṣā* or *daśavidhaparīkṣā*. Clinical symptoms were not directly documented by Ayurvedic physicians or those with in-depth understanding of Ayurveda. Considering these limitations, it is possible that symptomatology that is of relevance for Ayurvedic assessment may not have been recorded.

3.3. Disease profile in the light of review of classical ayurvedic literature {#sec3.3}
-----------------------------------------------------------------------------

We found that *Suśrutasaṃhitā* has described epidemic fevers presenting with cluster of symptoms like cough, breathing difficulty, vomiting and headache, which resembles fevers causing severe acute respiratory syndrome (SARS) *\[Su.S. Su.St, 6.19-20\]* \[[@bib32]\]. *Dalhaṇa*, the commentator additionally refers to symptoms like anosmia (*gandhājñāna*), which are of interest in understanding COVID-19. He also points to the nasal passages as the point of contact with the causative agent of the disease *\[Su.S. Su.St. 6.19-20\]* \[[@bib32]\]. *Suśrutasaṃhitā* does not refer to a specific disease as a well-defined nosological entity in this context, rather only hints at the possibility of epidemic outbreaks of severe respiratory illnesses that resembles SARS and COVID-19 like illnesses. The *Carakasaṃhitā* devotes an entire chapter for discussion on epidemics and points out how people with different consitutions can be affected by the same disease due to the influence of common etiological factors like air, water, place and time, but does not list or describe specific epidemic diseases *\[Ca.S. Vi.St. 3.3-6\]* \[[@bib33]\].

*Suśrutasaṃhitā* also lists fevers among diseases that are contagious *\[Su.S. Ni.St. 5--34\]* \[[@bib32]\]. Out of the eight broad categories of fevers described in Ayurveda, the *āgantujvaras* are caused by external agents *\[Ca.S. Ni.St. 1.7\]* \[[@bib33]\]. *Abhiṣaṅgajvara* is one of the sub-categories of *āgantujvara* which includes a sub-type of fever called *bhūtābhiṣaṅgajvara\[Ca.S. Ni.St. 3.111-112, 114--115\]* \[[@bib33]\]. *Cakrapāṇidatta* clarifies that *bhūta* means *viṣakṛmi* or a virulent organism*\[Ca.S. Sa..St.1.121\]* \[[@bib33]\]. Further, *Vijayarakṣita*, the commentator of *Mādhavanidāna* points out that diseases caused by *bhūtopasarga* (invasion of *bhūtas* like *viṣakṛmi*) can be contagious and spreads from person to person *\[Ma.Ni. 49.42--43\]* \[[@bib34]\]. Microorganisms and contagion were well recognised in Ayurveda classical texts. The term *kṛmi* generally denotes pathogenic organisms but also includes organisms which are microscopic and not visible to the naked eye (*kecid saukṣmyād adarśanāḥ*) *\[Ca.S. Vi.St. 7.11\]* \[[@bib33]\]. Such *kṛmis* are *sahaja* (natural) or *vaikārika* (pathogenic) *\[Ca.S. Vi.St. 7.11\]* \[[@bib33]\]. *Cakrapāṇidatta* points out that the natural microorganisms in the body are not counted here and this is perhaps a very early allusion to the human microbiome. He, also refers to variation in nomenclature of *kṛmis* prevalent in other geographical regions *\[Ca.S. Vi.St. 7.9\]* \[[@bib33]\]. There is an opinion in classical texts that *viṣamajvara*, a variation of *sannipātajvara* can be caused by *bhūtābhiṣaṅga* (invasion by *bhutas*) *\[Su.S. Ut.Ta. 39.68\]* \[[@bib32]\]. Many herbs and medicines in Ayurveda which have *kṛmighna* properties exhibit antibacterial and antiviral activity \[[@bib35]\]. *Rakṣoghnakarma* or fumigation with herbs, which is recommended to prevent wounds from suppurating and also for purifying air have been found to exhibit antimicrobial activity also against viruses \[[@bib32]\]. Such herbs described in classical Ayurvedic texts are candidates for research and discovery of antiviral agents against specific viruses. In the commentary of Dalhana, there is a quotation from Bhoja that alludes to the migration of *kṛmis* from body of one person to the other while explaining how the movement of the mind from one body to another body after death is invisible *\[Su.S. Sa.St. 1.16\]* \[[@bib32]\]. This is a rare reference in classical texts hinting at the invisible migration of pathogens from one person to the other. Avoiding modes of transmission of diseases described in Ayurveda like physical contact (*gātrasaṃsparśa*), inhalation (*nihśvasa)*, sitting and sleeping together (*sahaśayyāsanāt*) *\[Su.S. Ni.St. 5.33-34\]* \[[@bib32]\] and even keeping away from places where there is chance of exposure (*sthānaparityāga*) have been advised as measures to mitigate the epidemic advised in *Suśrutasaṃhitā \[Su.S. Sui.St. 6.20\]* \[[@bib32]\]. *Carakasamhitā* specifically advises self-protection (*ātmagupti*) and relocating to places that have not been affected (*śivānāṃ janapadānāṃ sevanaṃ*) *\[Ca.S. Vi.St. 3.15-16\]* \[[@bib33]\].

In fevers caused by *abhiṣaṅga* in general and even in *bhūtābhiṣaṅga* specifically, there is a tendency for derangement of all three *doṣas* leading to what is technically known as *sannipātakopa \[Ca.S. Vi.St. 3.115-116\]* \[[@bib33]\] *\[As·Hr. Ni.St. 2.43\]* \[[@bib36]\]. Even in *āgantujvaras* caused by extrinsic agents, *doṣa* imbalance occurs eventually *\[As.Hr.Ci.St.1.171\]* \[[@bib36]\].

With this background, it was most appropriate to review the portions of classical Ayurvedic texts dealing with *jvara* and specifically the *bhūtābhiṣaṅgaja* type of *āgantujvara* and *sannipātajvara*.

*Carakasamhitā* describes general features of *sannipātajvara* and further describes thirteen types based on variations in *dosa* dominance *\[Ca.S. Ci.St. 3.103-109\]* \[[@bib33]\]. On the other hand, *Suśrutasaṃhitā* and the works of *Vagbhata* describe only general features of *sannipatajvara \[Su.Sa. Ut.Ta. 39.35--38\]* \[[@bib32]\] *\[As·Hr. Ni.St. 2.27-33\]* \[[@bib36]\]. *Dalhaṇa* points out that even though *sannipātajvaras* are classified into thirteen types, by finer subclassification and gradation of *doṣa* dominance as well as involvement of *dhātus*, *sannipāta* can present in infinite ways *\[Su.Sa. Ut.Ta. 39.43-44\]* \[[@bib32]\]. Indeed, later texts like *Yogaratnākara* and *Bhāvaprakaśa* have identified and named many more *sannipātajvaras \[Yo.Ra.Jvaracikitsa. 2--12\]* \[[@bib37]\] like *kaṇṭhakubjajvara* which presents with acute respiratory distress *\[Bh.Pr. Ma.Kh. 1-439-526\]* \[[@bib38]\]. A textbook called *Jvaranirṇaya* was composed by *Narāyanapaṇḍita* which gives the most detailed and classified descriptions of *jvara* in the entire Ayurvedic literature. The chapter on *tridosajajvara* provides a comprehensive categorization and sub-classification of *sannipātajvara \[Jvaranirnaya, Tridosaja, 1--241\]* \[[@bib39]\]. This text helps very much in understanding how to clinically assess and classify *sannipātajvara* on the basis of multiple parameters compiled from other texts like nature of combination of *doṣas (samavāyibheda)*, the variability of dominance of *doṣas* in a particular type of *sannipātajvara*, the pattern of fever (continuous, intermittent and so on), seasonality or otherwise, progression in the *dhātus*, clinical course as well as duration. Most interestingly, newer presentations of *sannipātajvara* documented in various texts in the evolutionary history of Ayurveda have all been compiled together appened by the author\'s own additions in between. Some *sannipatajvaras* are described only in terms of the variation in *doṣa* imbalance while specific names are given for other sannipatajvaras like *vaidārika*, *visphuraka*, *papphaṇa* and so on. The *Jvaranirṇaya* clearly points to the need for studying and classifying new presentations of *sannipātajvara,* which is an approach that assumes relevance in the study of COVID-19

In recent times, Gananatha Sen in his work *Siddhāntanidāna* discusses about changes in clinical presentations of diseases due to the influence of place and time as well as influence of varied etiological factors *\[Sid.Ni. \]* \[[@bib40]\]. He points out that textual descriptions of diseases may not match with clinical presentations seen today. In fact, classical Ayurvedic texts provide guideline for analysis of diseases not listed in the literature. *Aṣtāṅgahṛdaya* points out that analytical understanding of a disease in terms of its finer constituents like *samprāpti*, site of manifestation and specific *nidānas* is more important than identifying it by its name *\[As.Hr.Su.St.12.64-66\]* \[[@bib36]\]. A new disease (*anuktavyādhi*) can be understood by study of *nidāna*, *doṣa*, *sthāna* \[[@bib33]\] and other factors involved in the disease causation, progress and clinical outcomes as evidenced in texts like *Mādhavanidāna \[Ma.Ni.25 and 51\]* \[[@bib34]\]

4. Discussion {#sec4}
=============

COVID-19 being a new disease, we did not expect to find an exactly matching description in the classical Ayurvedic texts. The review of the classical Ayurvedic literature suggests that a careful analysis of the descriptions of *sannipātajvara* and correlation with the modern clinical profile of COVID-19 will be helpful in understanding whether this disease can be classified within the generic categorisations of *jvara* in Ayurveda. On the other hand, it will also help us to find out if COVID-19 needs to be classified as an independent disease entity altogether.

4.1. COVID-19 as a type of *jvara* {#sec4.1}
----------------------------------

Fever, the most frequently reported symptom of COVID-19 is seen in 89--99% of patients. On this basis, we can consider COVID-19 as a type of *Jvara*. In the cohort of COVID-19 patients that we analysed, fever was not seen in three patients. However, the course of the disease was very mild in these patients and we infer that they remained in the *pūrvarūpa* (prodromal) stage without progressing to full fledged disease. Further studies focused on careful analysis of clinical symptoms with respect to disease progression is needed to make clear distinctions of the clinical stages of COVID-19 from the Ayurvedic perspective.

4.2. COVID-19 as a type of *sannipatajvara* based on clinical symptoms {#sec4.2}
----------------------------------------------------------------------

Fever in COVID-19 is mild to moderate, which is typical of fever with dominance of *vāta* and *kapha* as understood in Ayurveda (*madhyamavegajvara*) *\[Ca·S.Ci.St.3.86-87\]* \[[@bib33]\]. High grade fever has been reported in exceptional cases. Other major symptoms like cough and breathing difficulty as well as pneumonia and Acute Respiratory Distress Syndrome (ARDS) point to involvement of *vāta* and or *kapha \[Ca·S.Ci.St. 17.45\]* \[[@bib33]\]. Associated symptoms like chills, shaking, rhinorrhoea, headache, sputum, nausea, vomiting and anorexia are also generally indicative of *vāta* and *kapha* dominance *\[As.Hr.Ni.St.1.25\]* \[[@bib36]\]. Such a presentation is suggestive of *vātakaphajvara*. However, some symptoms like confusion, sore throat, haemoptysis and diarrhoea, which are also seen in COVID-19 patients indicate the involvement of *pitta* as do the sporadic reports of skin eruptions and dizziness *\[As.Hr.Ni.St.1.18-20\]* \[[@bib36]\]. Since the clinical features of COVID-19 invariably indicates imbalance of all the three *dosas* with fever as a main symptom, the possibility of *sannipātajvara* was also examined. We found many general features of *sannipātajvara* can be seen in COVID-19. Fever, cough, breathing difficulty, headache, sore throat \[[@bib12]\], anorexia, confusion, hemoptysis \[[@bib41]\], arthralgia \[[@bib42]\], conjunctivitis \[[@bib43]\], delirium, sleep disturbances \[[@bib44]\], seizures \[[@bib45]\] dizziness \[[@bib46]\], abnormal breath sounds \[[@bib47]\] fatigue \[[@bib48]\] oral thrush \[[@bib49]\] thirst, dehydration and reduced output of urine \[[@bib50]\], affliction of heart \[[@bib51],[@bib52]\], skin rashes \[[@bib19]\], loss of speech, deviated eyes \[[@bib53]\] inflammation of nasal and respiratory passages and delay of *doṣapāka* are symptoms of *sannipātajvara \[Ca·S.Ci.St.3.103-109\]* \[[@bib33]\] seen in COVID-19. For a detailed matching of these symptoms with COVID-19, see [Table 3](#tbl3){ref-type="table"}. One of the thirteen types of *sannipātajvara* described in *Carakasamhitā* shows some symptoms that are similar to COVID-19 but a one to one correlation seems to be inappropriate. The type of *sannipātajvara* with dominance of *vāta* and *kapha* (*vātaśleṣmolbaṇe*), but mild involvement of *pitta* (*pittāvare*) presents with fever, chills, cough, anorexia, thirst, burning sensation and aches *\[Ca·S.Ci.St.3.92\]* \[[@bib33]\]. The data from the cohort of 14 patients supports these observations. Generally, the symptom profile of the cohort represented features of *vātakaphajvara* with cough, sore throat and fever reported as main symptoms and the twenty symptoms reported pointed towards *sannipātajvara.* Nausea and anorexia were also reported in some patients as well as diarrhea showing the association of *pitta* along with *kapha* in the *koṣtha.*

4.3. COVID-19 as a type of *sannipātajvara* based on clinical course of the disease {#sec4.3}
-----------------------------------------------------------------------------------

The clinical course of COVID-19 also points to the possibility of *sannipātajvara*. *Sannipātajvara* becomes incurable or difficult to manage if the *doṣa* does not undergo *pāka* (*doṣe vibaddhe*) due to dysfunction of *agni* (*agnau naṣte*) and if the full range of symptoms manifest *(sarvasampūrṇalakṣana)*. Even if patients recover, there are chances of residual disabilities (*vaikalya*) *\[As.Hr.Ni·St. 2.34\]* \[[@bib36]\]. According to *Suśrutasaṃhitā*, *sannipātajvara* typically runs a mild or moderate course for one or two weeks or even more and then becomes severe and the patient either recovers from the crisis or dies *\[Su.S.Ut.Ta.39.45-46\]* \[[@bib32]\]. This is not characteristic of fevers caused by single *doṣas* or dual *doṣas*. *Sannipātajvara* can present with life threatening events *\[Ca·S.Ci.St.3.109-110\]* \[[@bib33]\]. COVID-19 can turn severe after running mild to moderate course. When it turns critical, mortality is high and even if patients recover residual disabilities have been reported. It is intriguing to note that in our cohort of 14 patients, the patient (P6) who died exhibited the maximum number of thirteen clinical symptoms. It must also be mentioned that in this patient, we observed the triad of symptoms indicating bad prognosis -- *autsukya* (increased anxiety), *moha* (confusion), *arati* (irritability and restlessness) *\[As·Hr. Su.St.1.1\]* \[[@bib36]\].

4.4. COVID-19 as an unlisted type of *vatakaphapradhānasannipātajvara* based on review of texts {#sec4.4}
-----------------------------------------------------------------------------------------------

The features of COVID-19 do not match exactly with descriptions of specific *sannipātajvaras* in classical texts, though it exhibits characteristics of *sannipātajvara* in general. For these reasons, we propose that COVID-19 presents clinical features pointing to an Ayurvedic diagnosis of a type of *vātakaphapradhāna sannipātajvara with pittānubandha* which needs to be described and documented by clinical studies. From the etiological perspective, it is of exogenous origin (*āgantu*).

4.5. Understanding COVID-19 based on analysis of *nidana*, *dosa* and *dusya* {#sec4.5}
-----------------------------------------------------------------------------

As discussed earlier, an unlisted disease can be studied by analysis of *nidāna* (etiology), *doṣa* and *dusya.*

### 4.5.1. *Nidāna* (etiology) {#sec4.5.1}

Being an infectious disease and with the SARS-CoV-2 well identified as the causative agent, COVID-19 can be classified as an *āgantu* disease. Not getting in contact with an infected person or contaminated surfaces is the best known and most effective way to prevent the disease. As pointed out earlier, *bhūtābhiṣaṅga* by *viṣakṛmi* is a very plausible understanding of the nidana or etiology of COVID-19 from the Ayurvedic viewpoint. Finer discussions are warranted before viruses can be classified under a specific category of extraneous causative agents described in the classical texts, which is not being attempted in this paper.

### 4.5.2. *Nidāna*, *doṣa*, *dūṣya* interactions (agent--host interactions) {#sec4.5.2}

#### 4.5.2.1. The transition of pathogenesis from extrinsic to intrinsic phase {#sec4.5.2.1}

Virus - host interactions lead to disturbances of *doṣas* and subsequent development of pathogenesis. *Carakasamhitā* clarifies in that *āgantujvara* (fevers of extraneous origin) does not disturb the *dosas* for a short period of time. In this stage, symptoms may be seen without indication of *doṣa* imbalance *\[Ca·S·Ni.St.1.30\]* \[[@bib33]\]. *Cakrapāṇidatta* clarifies that this phase lasts for about 3--7 days after which signs of *dosa* imbalance manifest *\[Ca·S·Ni.St.1.30\]* \[[@bib33]\]. *Vagbhata* emphasizes that the fever will progress only if the *doṣa* imbalance occurs within this period *\[As.Hr.Ci.St.1.172\]* \[[@bib36]\]. It can be inferred from this discussion that individuals in whom *doṣa* imbalance does not get established, may present without symptoms or mild symptoms and do not progress to critical stages. As pointed out earlier, three patients in our cohort did not develop fever or progress into severe or critical stages and exhabited only other mild symptoms until tested negative. The progression of the disease interpreted on the basis of disturbances of the *doṣas* is critical for developing treatment strategies in Ayurveda. The clinical course of all *jvaras* (fevers) have been divided into specific stages in Ayurveda. The early stage of fever is called *tarunajvara* with a general predominance of *kapha* and *ama\[Ca·S.Ci.St.3.133-136\]* \[[@bib33]\]. The late stage of fever is called *jirnajvara* with a dominance of *vata* and *pitta* as well as resolution of *ama \[Ca·S.Ci.St.3.133-136\]* \[[@bib33]\].

#### 4.5.2.2. The manifestation of dosa imbalance {#sec4.5.2.2}

When there is dry cough, the dominance of *vāta* should be inferred *\[As.Hr.Ni.St.3.22-24\]* \[[@bib36]\]. If cough is associated with sputum, then a dominance of *kapha* should be inferred *\[As.Hr.Ni.St.3.26-27\]* \[[@bib36]\]. The degree of involvement of these two *doṣas* can be understood by analysing the consistency of the sputum - whether it is thick or thin, with the former indicating a complete dominance of *kapha \[As.Hr.Ni.St.3.26-27\]* \[[@bib36]\]. If there is high grade fever, then dominance of *pitta* should be inferred. These presentations can vary from person to person. A combination of these features would call for a finer analysis of the degree of involvement of the three *doṣas* in a *sannipāta* situation. Scanty sputum was reported only in few patients in the cohort that we studied, pointing to *vāta* dominant *kāsa* in a group of aged people. The presentation of the disease in asymptomatic, presymptomatic, mild, moderate, severe or critical manner depends on the outcomes of the interactions between *nidāna*, *doṣa* and *dūṣya.* It is clearly mentioned that when these factors are in opposition there is resistance to disease (*vikāravighātabhāva*) *\[Ca·S·Ni.St.3.4\]* \[[@bib33]\]. Host factors that initiate resistance to disease (*vyādhikṣamatva* or *vyadhyutpādapratibandhakatva*) are dependent on *bala* (innate strength of the body)*\[Ca·S.Su.St.28.6\]* \[[@bib33]\]. *Bala* is a broad term that includes *agnibala* (strength of digestive and metabolic processes), *dhātubala* (strength of body elements) and *dehabala* (strength of body). *Ojas* is the byproduct of metabolic processes taking place in all the *dhātus\[As.Hr.Su.St.11.37\]* \[[@bib36]\]. The *bala* of the body is primarily dependent on *ojas\[As.Hr.Su.St.11.38\]* \[[@bib36]\]. In the treatment of *jvara*, it is clearly mentioned that when *agni* is stabilized, *balam* and *ojas* are increased *\[As.Hr.Ci.St.1.3\]* \[[@bib36]\]. Fever persists only in the absence of *dehabala* and *dhātubala \[As.Hr.Ci.St.1.84\]* \[[@bib36]\]. It has been pointed out that *bala* by itself can bring back the balance of the *doṣas \[As.Hr.Ci.St.1.84\]* \[[@bib36]\]. Strengthening the host immunity would be an important therapeutic strategy from the Ayurvedic viewpoint. It has been observed that a robust immune response across different cell types was associated with clinical recovery, similar to what we see in influenza, in COVID-19 cases also \[[@bib54]\]. This corroborates with the general approach to *jvaracikitsā* in Ayurveda that emphasises the preservation and enhancement of *bala* for uncomplicated recovery from the disease *\[As.Hr.Ci.St.1.2\]* \[[@bib36]\].

#### 4.5.2.3. The sites of the agent--host interactions {#sec4.5.2.3}

From an Ayurvedic point of view, the primary site of the disease is the *prāṇavaha srotas*, which includes both the upper respiratory and lower respiratory tracts *\[Ca·S.Vi.St.5.8\]* \[[@bib33]\]. In COVID-19, the lower respiratory tract is the centerstage of the pathological events that unfold in the course of the progression of the disease. The most common respiratory symptom seen is cough, which is usually dry. It is usually accompanied by mild to moderate fever. This pattern was clearly observed in the cohort of patients with all patients reporting cough and eleven patients, fever. In some patients, the gastrointestinal system is also affected. The possibility of the virus entering through the mouth and first affecting the gastrointestinal tract before affecting the respiratory system has also been discussed in published papers \[[@bib55]\]. In such cases, patients present with symptoms related to *pitta* and *kapha* like diarrhoea, nausea or vomiting. This suggests the involvement of *kostha* and *annavahasrotas* from the Ayurvedic perspective *\[Ca·S.Su.St.11.42-43\]* \[[@bib33]\]. Gastrointestinal symptoms were also reported in the data from the cohort of patients that we reviewed. Considering the fact that fever is the main symptom, the involvement of *rasavahasrotas* is to be inferred. Respiratory symptoms like cough and dyspnea indicate the involvement of *pranavaha*, *udakavaha* and *annavaha srotases \[As.Hr.Ni.St.4.3--4\]* \[[@bib36]\]. Clotting of blood has been reported in many patients suggesting the involvement of *raktavahasrotas* also. In some patients, there are generalised symptoms like skin eruptions indicating involvement of *śākhā \[Ca·S.Su.St.11.42-43\]* \[[@bib33]\]. In others, myalgia and arthralgia have been reported which indicates involvement of *madhyamarogamārga\[Ca·S.Su.St.11.42-43\]* \[[@bib33]\]. The *dhātus* involved in COVID-19 can be tentatively considered as *rasa* and *rakta*. The damage to heart (*hṛdaya*), brain (*śiras*) and kidneys indicate the affliction of the vital organs (*marmas*) by the disease *\[Ca·S.Su.St.11.42-43\]* \[[@bib33]\].

#### 4.5.2.4. The crisis in advanced stages {#sec4.5.2.4}

As the disease progresses, the efficiency of *ojas* is compromised and a crisis can develop. Such a presentation is seen in critical COVID 19 cases, characterized by disruption of immune system \[[@bib56]\] leading to cytokine storm and ARDS, which correlates with *ojonirodha* described by *Suśrutasaṃhitā* in the context of severe *sannipātajvara\[Su.S.Ut.T.39.43-45\]* \[[@bib32]\]. One patient in the cohort of our study progressed to critical stage and died. It is pertinent to point out that this patient reported negative on 18th day but became positive again on 24th day indicating a weakened immune system. The commentator *Vijayarakṣita* points out that accumulation of metabolic byproducts due to aberrations in digestion and metabolism as well as the disturbances in *doṣas* is called in Ayurveda as *āma \[Ma.Ni.25.1--5\]* \[[@bib34]\]. The development of *āma* goes hand in hand with the pathogenesis. In a disease with derangement of all three *doṣas* (*doṣasaṃmūrchana*), the *āma* can become *āmaviṣa* (biochemical changes leading to sepsis and septic shock)*\[As.Hr.Su.St.13.26\]* \[[@bib36]\]. There is an opinion amongst Ayurvedic physicians that the concept of *viṣa* must be considered in the etiology of the disease.

### *4.5.3*. *Nidānapañcaka* (five diagnostic descriptors) and *satkriyakala* (clinical course) of COVID-19 {#sec4.5.3}

An attempt is being made here to give a preliminary outline of the *nidānapañcaka* (five diagnostic descriptors) and *ṣaṭkriyākāla* (clinical course of the disease).

#### *4.5.3.1*. *Nidāna* (etiology) {#sec4.5.3.1}

The primary cause of COVID-19 is the SARS-CoV-2, which can be classified as an *āgantuhetu* in Ayurveda. The role of additional supportive factors like weather, diet, lifestyle and other host related factors that influence the clinical course and progression of the disease need to be studied further.

#### *4.5.3.2*. *Pūrvarūpa* (prodromal symptoms) {#sec4.5.3.2}

Without careful assessment of a large number of patients, it is not possible to meticuloulsy document the prodromal symptoms of COVID-19. In principle, we can say that symptoms that do not give a clear indication of a *doṣa* imbalance can be classified as *pūrvarūpa\[Ma.Ni.1.5-6\]* \[[@bib34]\]. Since fever is the most common symptom of COVID-19, presentation of symptoms without fever can also be considered as the prodromal stage of the disease. As pointed out earlier, three patients in the cohort of COVID-19 patients that we studied did not report fever and did not progress to severe or critical stage. Asymptomatic and presymptomatic patients will need to be studied closely to profile the prodromal signs of COVID-19. Pre-symptomatic patients develop symptoms later, but asymptomatic patients can remain so until they test negative. A seemingly unnoticed symptom like anorexia and tiredness may be the indication of the development of *āma* in the prodromal stage and should not be ignored. Some patients may only notice anosmia \[[@bib57]\]. Sometimes asymptomatic COVID-19 patients can show lung damage in CT scans or develop severe disease in the later course of the disease \[[@bib58]\].

#### *4.5.3.3*. *Rupa* (clinical symptomatology) {#sec4.5.3.3}

The key symptoms of COVID-19 are fever (*jvara*), cough (*kāsa*) and shortness of breath (*śvāsa*), which points to *vātakapha* dominance. Association of *pitta* related symptoms and clinical course described earlier indicate that COVID-19 is a type of *sannipātajvara*. The wide variations in clinical presentations of COVID-19 points to the necessity of identifying sub types based on symptom clusters indicating variations in the *tridoṣa* imbalance. This calls for a meticulous observation of larger number of patients based on Ayurvedic parameters. Clustering of symptoms was observed in our cohort of COVID-19 patients indicating finer variations in *doṣavikalpa*, which needs further examination and analysis by a more comprehensive clinical study.

#### *4.5.3.4*. *Upaśaya* (therapeutic response) {#sec4.5.3.4}

Ayurvedic clinical studies need to be conducted to elicit the *upaśaya* (positive) or *anupaśaya* (negative) response to confirm the provisional assessment of *doṣa* imbalance and other Ayurvedic parameters *\[Ca·S.Vi.St.4.7\]* \[[@bib33]\]. This is all the more relevant to distinguish between *prakṛtisamasamavāya* (when clinical symptoms reflect underlying *doṣa* imbalance) or *vikṛtiviṣamasamavāya* (where clinical symptoms do not reflect underlying *doṣa* imbalance) type of *doṣa* imbalance as clarified by *Cakrapāṇidatta \[Ca·S.Ci.St.3.89-109\]* \[[@bib33]\]. In the *Jvaranirṇaya*, the importance of making this clinical distinction is emphasised by classification of both dual dosa and *sannipāta* fevers into the above mentioned two categories in the first verse of the chapter itself *\[Jvaranirṇaya, Tridosaja.1\]* \[[@bib39]\].

#### 4.5.3.5. Saṃprāpti (pathogenesis) {#sec4.5.3.5}

Being an *agantu* disease, the disease progresses clinically only when the *dosa* imbalance is initiated. *Saṅkhyāsaṃprāpti* -- At this point of time, we suggest that COVID-19 is understood as a single disease. However, further clinical studies may help us to sub-classify COVID-19 on the basis of variations in *dosa* imbalance. *Vikalpasaṃprāpti* -- On the basis of our study, a dominance of *vāta* and *kapha* accompanied by mild degree of *pitta* is seen in the presentation and clinical course of the disease. The possibility of variations in different stages of presentation must be further studied clinically. *Prādhānyasaṃprāpti* -- COVID-19 is an independent disease (*svatantravyadhi*) though it can worsen in the presence of pre-existing co-morbidities. However, pneumonia, ARDS, fatal cardiac events, stroke and such other complications arise in severe and critical cases. The status of these conditions in terms of dependance (*paratantrata*) and complication (*upadrava*) *\[Ca·S.Ci.St.21.40\]* \[[@bib33]\] as well as independent co-morbidities (*vyādhisankara*) *\[Ma.Ni.2.33\]* \[[@bib34]\] needs to be further studied. Complications may require urgent and exclusive attention as pointed out in *Carakasamhitā*. Four patients in our cohort developed *upadravas* or complications while seven presented with a *vyādhisankara* situation with co-morbidities. *Balasaṃprāpti* -- Even though the singular cause of COVID-19 is the SARS-CoV-2, the severity of the disease highly varies from individual to individual. Further studies are needed to understand the role of extrinsic and intrinsic factors that can influence the severity of the disease. Air pollution has been reported to worsen outcomes in COVID-19. On the other hand, the influence of diet and lifestyle is not as well understood. *Kālasaṃprāpti* -- We do not have adequate data to understand the relation between the manifestation of symptoms in relation to diurnal and seasonal variations. Data is also inadequate to conclude whether severity of COVID-19 is linked to cold or warm weather. Meticulous clinical observations are needed to be able to identify specific *doṣa* imbalances by studying the pattern of fever and other symptoms in relation to different times of the day and night.

### *4.5.4*. *Ṣaṭkriyākāla* (clinical course of the disease) {#sec4.5.4}

Further clinical studies are needed to build a detailed description of the clinical course of COVID-19 from an Ayurvedic perspective. An attempt is being made in this paper to sketch a rough outline of the *ṣaṭkriyākāla* pointing out the gaps that will need to be addressed by conducting further studies.

#### 4.5.4.1. The Caya, Prakopa and Prasara {#sec4.5.4.1}

The *Caya, Prakopa* and *Prasara* stages are difficult to distinguish in an *āgantu* disease. We can tentatively correlate the incubation period of COVID-19 with this phase. This stage need not be totally asymptomatic and symptoms indicating viral infection (*hetuvyañjakalakṣana*) may be present but yet not noticed *\[Ca·S.Su.St.18.5\]* \[[@bib33]\]. Loss of smell and taste, sore throat, diarrhea and such non-specific symptoms have been reported as the only presenting signs of COVID-19 infection. Being the *āgantu* phase of pathogenesis, *doṣa* specific symptoms will not be seen.

#### 4.5.4.2. The Stage of Sthānasaṃsraya {#sec4.5.4.2}

The Stage of *Sthānasaṃsraya* is the stage in which the prodromal symptoms (*purvarupa*) are manifesting. This stage is not well demarcated in available clinical documentation of COVID-19. Certain presentations with mild symptoms could be potentially classified as the stage of *purvarupa* but extensive clinical studies are required for a clear understanding.

#### 4.5.4.3. The Stage of Vyakti {#sec4.5.4.3}

The Stage of *Vyakti* is the symptomatic stage of the disease, which can be mild to moderate or severe. There is further scope for further classification of the clinical presentation of COVID-19 on the basis of specific symptom clusters related to variations in *dosa* imbalances and location of the disease process.

#### 4.5.4.4. The Stage of *Bheda* {#sec4.5.4.4}

The Stage of *Bheda* represents the complications of COVID-19, which is characterized as the critical stage with severe pneumonia, ARDS and hypoxia. This stage of COVID-19 is associated with higher rate of mortality.

See [Fig. 1](#fig1){ref-type="fig"} for a diagrammatic representation of the clinical course of COVID-19Fig. 1Clinical course of COVID-19.Fig. 1

### 4.5.5. *Sadhyāsādhyata* (prognosis) {#sec4.5.5}

In the light of information available from published studies, we infer that if *kapha* is not deranged or depleted, the outcomes are good as are seen in children who have *kapha* in the natural or *pṛākṛta* state *\[Ca·S.Su.St.17.117\]* \[[@bib33]\]. *Kapha* in the natural state enhances the *bala* of the system. In old age, there is depletion of *kapha* and increase of *vāyu*. Such patients are at risk for progression of disease to severe stage and poor outcomes \[[@bib22]\]. In diseases where there is derangement of *kapha* like diabetes, the prognostic outlook is not good. In diseases like hypertension with derangement of *vāta* a bad prognosis is expected. The one patient who died in the cohort of our study had hypertension as well as cardiac disease and was 70 years old. However, it is clear that while old age and co-morbidities put the patient at a higher risk of complications and death, with proper medical attention and supportive care, such patients can also recover from the disease. In our cohort, thirteen out of fourteen patients were aged between 64 and 77 years and recovered. All those who developed ARDS had co-morbidities.

Other factors like *doṣaprakṛti (tridoṣa* constitution) of the individual, the geographical region (*deśa)* as well as the prevailing season (*kāla)* during the outbreak may have prognostic implications for COVID-19, which deserves attention. We have not done an extensive analysis of the *deha*, *deśa, kāla* or *prakṛti* in this study. However, based on this preliminary understanding of the disease progression and the *doṣavikalpa*, an assumption can be made that those individuals with *vātakapha prakṛti* and tendency for *pitta* aggravation may be more susceptible to developing complications. Adequate data is not available for further discussion on this topic in this paper. See [Table 4](#tbl4){ref-type="table"} for a summary of the key elements of the Ayurvedic clinical profile of COVID-19.Table 4Symptoms of sannipatajvara seen in COVID-19.Table 4General Symptoms of SannipātajvaraTextReported Occurrence in COVID-19TEMPERATURE1jvaraḥ (fever)C, S, VYESVery commonAll stages2kṣaṇē dāhaḥ kṣaṇē śītam (alternating heat and cold feeling)C,S,VNot reported**SWEATING**3muhuḥ svedaḥ (repeated sweating)VYESSometimesRandom4atisvedaḥ (excessive sweating)VYESSometimesSevere/Critical5asvedaḥ (absence of sweating)VNot reported**RESPIRATORY SYMPTOMS**6kāsaḥ (cough)C,VYESVery commonAll stages7śvāsaḥ (dyspnoea)C,S,VYESCommonAll stages8kaṇṭhaḥ śūkairivāvr̥taḥ (sore throat)C,VYESCommonAll stages9svarasādaḥ (hoarseness of voice)VYESSometimesRandom10srōtasāṁ pākaḥ (inflammation of nasopharynx, oropharynx and respiratory passages)C,SYESSometimesSevere/Critical11pratataṁ kaṇṭhakūjanam (abnormal breath sounds in throat region)C,SYESSometimesSevere/Critical12ṣṭhīvanaṁ raktapittasya kaphēnōnmiśritasya ca (hemoptysis)C,VYESRareRandom**GASTROINTESTINAL SYMPTOMS**13arucih (anorexia)C,SYESCommonRandom14gurutvamudarasya (heaviness of abdomen)CNot reported15malasaṃsaṅgaḥ (constipation)VNot reported16malānāṃ alpaśo pravṛttiḥ (reduced defecation)VNot reported17malānāṃ ati pravṛttiḥ (diarrhoea)VYESCommonRandom18paridagdhā kharasparśā jihvā (coarse and inflamed appearance of tongue)C,VYESRareRandom19rasanā paruṣā kr̥ṣṇā (rough and blackish appearance of tongue)SNot reported**PAIN AND ACHES**20asthirujā (pain in bones)C,S,VYESSometimesRandom21sandhirujā (pain in joints)C,S,VYESSometimesRandom22śirōrujā (headache)C,S,VYESSometimesRandom23piṇḍikāruk (pain in calf muscles)VYESSometimesRandom24pārśvaruk (pain in the flanks)VYES25sarujau karṇau (pain in ears)C,S,VNot reported**SLEEP DISORDERS**26nidrānāśō (insomnia)C,SYESSometimesRandom27divā mahānidrā (deep sleep during daytime)VYESSometimesRandom28niśi jāgaraṇaṃ (unable to sleep at night)VYESSometimesRandom29sadā nidrā (constant sleep)VYESSometimesRandom**SYMPTOMS SPECIFIC TO HEAD REGION**30śiraso loṭhanaṃ (dystonic movements, shaking, tremors of head)C,VYESRareSevere/Critical31sāsrāvē kaluṣē raktē ca darśanē (pink eye)C,SYESSometimesRandom32sasvanau karṇau (sound in ears)C,S,VNot reported33nirbhugnē darśanē (eyes are unsteady and deviated)C,S,YESRareSevere/Critical34śyāvadantatā (blackish discolouration of teeth)SNot reported35snigdhāsyatā (unctuous feeling in mouth)VNot reported**CARDIAC SYMPTOMS**36hr̥di vyathā (affliction of heart)C,S,VYESSometimesSevere/Critical**CUTANEOUS MANIFESTATIONS**37kōṭhānāṁ śyāvaraktānāṁ maṇḍalānāṁ ca darśanam (greyish red skin eruptions)C,VYESRareRandom**GENERAL SYMPTOMS**38srastāṅgatā param (loosenes of body parts)CNot reported39gurusrastāṅgasandhitā (heaviness and looseness of body parts)VNot reported40suptāṅgatā (numbness of body)SNot reported41stambhaḥ (stiffness)SNot reported42kr̥śatvaṁ nātigātrāṇāṁ (does not loose weight significantly)CNor reported43cirātpākaśca doṣāṇāṃ (delay in doṣapāka)C,S,VYESSometimesSevere/Critical44tr̥ṣṇā (thirst, dehydration)C,SYESCommonRandom45svēdamūtrapurīṣāṇāṁ cirāddarśanamalpaśaḥ (reduced sweating, output of urine and defecation)C,SReduced output of urine is reported in cases with dehydration46balabhraṃśa (loss of strength)VYESCommonRandom47bhramaḥ (dizziness)C,S,VYESSometimesRandom48tandrā (fatigue)C,SYESCommonRandom**CUTANEOUS MANIFESTATIONS**49mōhaḥ (confusion)C,SYESSometimesSevere/Critical50pralāpaḥ (delirium)C,SYESSometimesSevere/Critical51mūkatvaṁ (loss of speech)CYESSometimesSevere/Critical52madaḥ (inebriation)SNot reported53unmādaḥ (psychosis)SNot reported54gītanartanahāsyādivikṛtehāpravartanaṃ (abnormal behaviour)VNot reported55cētanācyutiḥ (loss of consciousness)SYESSometimesSevere/CriticalTable 5Ayurvedic clinical assessment of COVID-19.Table 5Nature of DiseaseSaṅkrāmika (Contagious)Impact of DiseaseJanapadodhvaṃsa (Affects large number of human settlements)Disease CategoryJvara (Fever)Disease Sub CategoryĀgantujvara (Fever of exogeneous origin)Disease Sub TypeBhutābhiṣaṅgajvara (Fever caused by invasion of pathogens)Specific EtiologyViṣakṛmijanya (Caused by virulent pathogen)Doṣavaiṣamya (Nature of doṣa imbalance)Sannipāta (Derangement of all three doṣas)Doṣavikalpa (Granularity of doṣa imbalance)Vatakaphapradhāna Pittānubandha (Dominance of Vāta and Kapha with association of Pitta)Dūṣya (Body elements affected)Rasa (In early stage), Rakta (In late stage)Srotas (Affected body channels)Prāṇavaha, Udakavaha, Annavaha (Cough and Dyspnoea), Rasavaha (Fever), Raktavaha (Complications)Rogamārga (Disease Pathways)Koṣṭha, Śākhā (In early stage), Madhyama (In late stage)Upadrava (Complications)Śvāskṛcchratā (Shortness of breath), Marmopaghāta (Damage to vital organs)Sukhasādhyatā (Favourable Prognosis)Alpaliṅgatva (Mild Symptoms), Ekarogamārgatva (Affects only one disease pathway), Balam (Immunity), Yauvanam (Younger age)Kṛcchrasādhyatā (Difficulty to manage)Madhyaliṅgatva (Moderate Symptoms), Śvāsakṛcchratā (Shortness of breath), Śākhāgatatva (Involvement of external disease pathway)Asādhyatā (Bad Prognosis)Vibaddhadoṣatva (Doṣas in mutual opposition), Pūrṇalingatva (Full range of symptoms), Agnināśa (Digestive and metabolic crisis), Vārdhakya (Old age), Rogasaṅkara (Co-morbidities), Marmagatatva (Involvement of vital organs)

5. Limitations of the study {#sec5}
===========================

A critical analysis of the clinical presentation of the disease on the basis of the principles of Ayurvedic nosology suggests that COVID-19 can be categorized as *āgantuk*a type of *vātakaphapradhāna sannipātajvara* with *pittānubandhatva*. However, the granularity of the *doṣa* imbalance as well as its dynamic progression in the course of the disease warrants further investigation and analysis. The wide variation in the incubation period, clinical presentation, clinical course and outcomes of the disease is indicative of the complex interactions between the agent and host factors, which is understood in Ayurveda in terms of interaction between *nidāna*, *doṣa* and *duṣya*. The clinical course of the disease and its evolution into the critical stage in some patients with fatal outcome or disabilities after recovery is characteristic of the clinical course of *sannipātajvara* described in Ayurvedic texts. Further studies are needed to delineate the various clinical stages (*vyādhyavasthās*) of the disease to envisage specific therapeutic approaches.

This study has several limitations. At the very outset, we pointed out that Ayurvedic physicians did not have direct access to COVID-19 patients, which ruled out the possibility of a comprehensive clinical assessment of COVID-19 on the basis of Ayurvedic parameters. We have tried to demonstrate that this challenge can be circumvented to some extent by interaction and discussion with Allopathic doctors who are treating COVID-19 patients. However, such an exercise, even when strengthened by review of published literature and classical Ayurvedic literature can only serve the purpose of developing a preliminary clinical profile of COVID-19 from the Ayurvedic perspective. The gaps have been pointed out indicating the specific areas where further studies based on clinical consultation with COVID-19 patients will be needed.

The analysis of clinical data from Medanata demonstrates that it is possible for Ayurveda physicians to cooperate with Allopathic physicians treating COVID-19 patients and that interactions should be encouraged for developing a preliminary understanding of COVID-19 from an Ayurvedic perspective when Ayurvedic physicians do not have direct access to patients. However, it also reveals the challenges in gathering data that is clinically relevant for Ayurveda when Ayurvedic physicians are not directly involved in clinical examination of COVID-19 patients. A comprehensive Ayurvedic understanding of a new disease like this needs clinical examination of patients based on Ayurvedic parameters and a meticulous documentation of clinical symptoms.

6. Conclusion {#sec6}
=============

Based on a preliminary analysis of literature reporting clinical symptoms of COVID-19, study of clinical presentation of a cohort of COVID-19 patients and Medanta and a review of classical Ayurvedic literature, we suggest that COVID-19 can be classified as *āgantuka jvara* with a *vātakaphapradhānasannipāta* presentation. The dominance of *pitta* in certain stages of the disease and in some patients should be considered. However, COVID-19 needs to be further subclassified under the category of *vātakaphapradhānasannipātajvara* on the basis of a more detailed analysis of clinical symptomatology of a cross section of COVID-19 patients representing diverse populations from different geographical regions in the world.

This paper demonstrates that it is possible to develop provisional Ayurvedic clinical classifications of COVID-19 in consultation with modern medical doctors treating COVID-19 patients, in a regulatory environment that does not permit Ayurvedic doctors from directly managing COVID19 patients. Studies involving larger number of patients are needed to further develop the approach outlined in this paper and formulate a protocol that can be validated at the point of care. Since Ayurveda management is personalized, closer interactions of Ayurveda experts in hospital settings with patients tested positive is important to refine the clinical profiling.

In India, the Central Government has created an Interdisciplinary AYUSH research Task force for COVID -19. The Task Force has set-up several working groups to explore the various possibilities of integrating Ayurveda with standard of care to deal with the COVID-19 epidemic more effectively. In the meantime, the Government of Kerala announced and rolled out a protocol and program for integrating Ayurveda into the management protocol of COVID19, in the State. This initiative shall implement preventive, mitigative and rehabilitative programs based on Ayurveda for better management of the COVID-19 epidemic in the State. Several other State governments are exploring similar possible integrative approaches. Such policy decisions may create a better integrative environment in the future which underlines the significance of this study.
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